Search Results

You are looking at 1 - 1 of 1 items for

  • Author: A V Vinogradova x
Clear All Modify Search
A V Dreval
Search for other papers by A V Dreval in
Google Scholar
PubMed
Close
,
I V Trigolosova
Search for other papers by I V Trigolosova in
Google Scholar
PubMed
Close
,
I V Misnikova
Search for other papers by I V Misnikova in
Google Scholar
PubMed
Close
,
Y A Kovalyova
Search for other papers by Y A Kovalyova in
Google Scholar
PubMed
Close
,
R S Tishenina
Search for other papers by R S Tishenina in
Google Scholar
PubMed
Close
,
I A Barsukov
Search for other papers by I A Barsukov in
Google Scholar
PubMed
Close
,
A V Vinogradova
Search for other papers by A V Vinogradova in
Google Scholar
PubMed
Close
, and
B H R Wolffenbuttel Moscow Regional Scientific Research Clinical Institute, Department of Endocrinology, 61/2 Shepkina str., 129110 Moscow, Russia

Search for other papers by B H R Wolffenbuttel in
Google Scholar
PubMed
Close

Early carbohydrate metabolism disorders (ECMDs) and diabetes mellitus (DM) are frequently associated with acromegaly. We aimed to assess the prevalence of ECMDs in patients with acromegaly and to compare the results with those in adults without acromegaly using two population-based epidemiologic surveys. We evaluated 97 patients with acromegaly in several phases of their disease (mean age, 56 years and estimated duration of acromegaly, 12.5 years). An oral glucose tolerance test was done in those not yet diagnosed with DM to reveal asymptomatic DM or ECMDs (impaired glucose tolerance+impaired fasting glucose). Comparisons were made between patients with acromegaly and participants from the general adult population (n=435) and an adult population with multiple type 2 diabetes risk factors (n=314), matched for gender, age and BMI. DM was diagnosed in 51 patients with acromegaly (52.5%) and 14.3% of the general population (P<0.001). The prevalence of ECMDs was also higher in patients with acromegaly than in the general population and in the high-risk group; only 22% of patients with acromegaly were normoglycaemic. The prevalence of newly diagnosed ECMDs or DM was 1.3–1.5 times higher in patients with acromegaly compared with the high-risk group. Patients with acromegaly having ECMDs or DM were older, more obese and had longer disease duration and higher IGF1 levels (Z-score). Logistic regression showed that the severity of glucose derangement was predicted by age, BMI and IGF1 levels. In patients with acromegaly, the prevalence of DM and ECMDs considerably exceeds that of the general population and of a high-risk group, and development of DM depends on age, BMI and IGF1 levels.

Open access